HCW Biologics (NASDAQ:HCWB) Releases Quarterly Earnings Results

HCW Biologics (NASDAQ:HCWB) announced its earnings results on Friday. The company reported ($0.08) EPS for the quarter, Zacks reports. HCW Biologics had a negative return on equity of 2,516.84% and a negative net margin of 1,067.82%.

HCW Biologics Trading Up 0.5 %

Shares of HCWB traded up $0.00 during mid-day trading on Friday, hitting $0.30. 99,430 shares of the company traded hands, compared to its average volume of 3,882,125. The business has a 50-day moving average of $0.37 and a 200 day moving average of $0.44. HCW Biologics has a one year low of $0.21 and a one year high of $2.52. The stock has a market capitalization of $13.54 million, a price-to-earnings ratio of -0.30 and a beta of 0.71.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.